Our lab develops biomarker-driven strategies to enable early detection, risk stratification, and precision prevention. We combine mechanistic insight with clinically grounded assay development.
We aim to identify measurable biological signals that precede clinically evident cancer and enable non-invasive detection and surveillance.
Approach: curated cohorts, PRoBE-style principles when feasible, and clinically practical assay designs.
We focus on translation: building assays that are robust, scalable, and compatible with real clinical workflows.
Examples of translation priorities
We connect tissue-level biology to urine/tissue biomarkers and outcomes.
Methods (examples)
We leverage models to understand how early tumor-associated states evolve over time and how they shape measurable biomarker signals.
If you’d like to collaborate, please reach out via Contact.